Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term prophylactic N8-GP in previously treated patients with severe haemophilia A (Japan)
jRCT2080223895Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of octocog alfa in hemophilia A (3 arms), sponsored by Novo Nordisk. Started May 2018; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080223895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223895.